Bachem Signs Peptide-Protein Conjugate Contract with Axon Neurosciences
Bachem and Axon Neuroscience SE today announced that the two companies have entered into a collaboration under which Bachem manufactures Axon’s investigational API and supplies it as a finished dosage form under Bachem’s Clinalfa brand. Axon’s innovative product targeting Alzheimer’s disease consists of a peptide-protein conjugate and will enter phase I clinical trials in Europe.
Roman Sivak, CEO of Axon Neuroscience, comments: "We have chosen Bachem because of their stellar reputation for quality work and the wide range of services they provide, spanning from peptide API production to conjugates and fill finish activities."
Dr. José de Chastonay, Chief Marketing Officer of Bachem, added: "Bachem is proud to have been selected as the supplier for Axon’s innovative Alzheimer product. Manufacturing a peptide-protein conjugate as well as providing finished dosage forms for clinical trials are valuable services we provide and perfectly complementary to our key expertise in peptides."